Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Astellas to Submit Improvement Plans for Gene Therapy Trial by September over Patient Deaths
Last year, Astellas Pharma saw its AT132 gene therapy trial placed on a second clinical hold by the US FDA over patient deaths. Now, the company plans to submit improvement measures to the regulator by September this year, aiming to…
To read the full story
Related Article
- Another Patient Dies in Astellas’ Gene Therapy Trial, FDA Issues New Clinical Hold
September 15, 2021
- Astellas Pauses AT132 Gene Therapy Trial after Serious Adverse Event
September 2, 2021
- US FDA Lifts Clinical Hold for Audentes’ Gene Therapy AT132: Astellas
December 28, 2020
BUSINESS
- Sanofi Debuts Sarclisa SC, Cutting Dosing Time
August 28, 2026
- Daiichi Starts Global PIII of Datroway in Adjuvant Urothelial Cancer
August 28, 2026
- FDA Accepts Kowa’s Glaucoma Drug K-911 for Review
August 28, 2026
- Hokuriku Downpours Cripple Some Drug Deliveries; Wholesalers Report No Damage
August 28, 2026
- Shionogi, Susmed End Sales Partnership for Insomnia App
August 27, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…